CN Patent

CN116969937A — Bcl-2抑制剂

Assigned to Beone Pharmaceutical Suzhou Co Ltd · Expires 2023-10-31 · 3y expired

What this patent protects

本申请披露了一种式(I)的化合物，其用于抑制Bcl‑2野生型和突变的Bcl‑2两者，具体为Bcl‑2G101V和D103Y，以及一种使用本申请披露的化合物治疗失调凋亡疾病的方法。

USPTO Abstract

本申请披露了一种式(I)的化合物，其用于抑制Bcl‑2野生型和突变的Bcl‑2两者，具体为Bcl‑2G101V和D103Y，以及一种使用本申请披露的化合物治疗失调凋亡疾病的方法。

Drugs covered by this patent

Patent Metadata

Patent number: CN116969937A
Jurisdiction: CN
Classification: —
Expires: 2023-10-31
Drug substance claim: No
Drug product claim: No
Assignee: Beone Pharmaceutical Suzhou Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.